Shafaq news/According to Reuters, The European Commission said that it had given conditional approval for the use of antiviral Remdesivir in severe COVID-19 patients following an accelerated review process; making it the region’s first authorized therapy to treat the virus.

The move comes just a week after the European Medicines Agency (EMA) gave its go-ahead for the drug, produced by Gilead Sciences (GILD.O), to be used in adults and adolescents from 12 years of age who are also suffering from pneumonia and require oxygen support.

“We will leave no stone unturned in our efforts to secure efficient treatments or vaccine against the coronavirus”, said Stella Kyriakides, EU Commissioner for Health and Food Safety, in a statement.

It’s noteworthy that, The EU’s green light broadens the use of Remdesivir after it is approved as a COVID-19 therapy in Japan, Taiwan, India, Singapore and the United Arab Emirates, Gilead said on Friday.